Study Enrollment


Your details will not be published or shared.

Clinical Trial

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinsonís Disease

This research is studying a new experimental drug, NLY01, in a large number of persons to learn about its effects in people with early Parkinsons disease. Researchers want to know whether NLY01 helps lessen symptoms and signs of early Parkinsons disease and whether it slows the progression of Parkinson?s disease. .


Eligibility Criteria

  • Has been diagnosis with Parkinsons Disease PD Patient is 30 to 80 years old

Contact Information

    Buff Farrow

    (706) 721-2798

   bfarrow@augusta.edu

RESEARCH. INNOVATION. DISCOVERY.